Physician Assistant · Montebello, CA
NPI
1891932083
Since 2009
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2205 W. Beverly Blvd
Montebello, CA, 90640
Phone (323) 726-7601
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
631 services
Medicare patients, 2024
165
Average age 72
Drug cost, 2024
$3.1M
7,298 prescriptions
Company payments, 2025
$3,193
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jesus Zepeda was code 99213 (office e&m - established), 242 times for 129 patients. In total Jesus Zepeda billed 631 services in 9 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-10-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 242 | 129 | $56.13 | $14K |
| 82962 Clinical Chemistry | Office | 214 | 101 | $3.21 | $687 |
| 99214 Office E&M - Established | Office | 107 | 67 | $86.40 | $9,245 |
| 83036 Blood Count | Office | 49 | 40 | $9.52 | $466 |
| 99212 Office E&M - Established | Office | 13 | 12 | $13.30 | $173 |
By year: 2022 $23K for 424 services; 2023 $28K for 588 services; 2024 $24K for 631 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 214 | 101 | $3.21 | $687 |
| 83036 Blood Count | 49 | 40 | $9.52 | $466 |
Medicare prescription drug claims, 2024
In 2024, the drug Jesus Zepeda prescribed most often to Medicare patients was Ozempic (Semaglutide), with 707 prescriptions and refills. In total Jesus Zepeda wrote 7,298 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 707 | 955 | 136 | $884K |
| Levothyroxine Sodium Generic | 580 | 1,610 | 175 | $10K |
| Metformin Hcl Generic | 441 | 1,260 | 145 | $4,502 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 428 | 973 | 133 | $56K |
| Jardiance Empagliflozin | 394 | 627 | 88 | $358K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 326 | 786 | 127 | $40K |
| Mounjaro Tirzepatide | 294 | 334 | 55 | $343K |
| Humalog Kwikpen U-100 Insulin Lispro | 291 | 598 | 98 | $70K |
| Atorvastatin Calcium Generic | 200 | 590 | 70 | $2,334 |
| Glipizide Er Glipizide | 199 | 562 | 65 | $3,309 |
| Metformin Hcl Er Metformin Hcl | 190 | 527 | 72 | $2,466 |
| Tresiba Flextouch U-100 Insulin Degludec | 147 | 328 | 38 | $84K |
| Synthroid Levothyroxine Sodium | 144 | 290 | 30 | $11K |
| Repaglinide Generic | 118 | 301 | 35 | $3,508 |
| Trulicity Dulaglutide | 113 | 151 | 33 | $143K |
Brand drugs: 4,124 claims; generic drugs: 2,505 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jesus Zepeda $3,193 ($3,193 in general payments such as food, travel and fees) from 24 companies. The largest payer was Amgen Inc. with $504.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 18 | $504 |
| Novo Nordisk Inc NVO | 17 | $473 |
| Dexcom, Inc. DXCM | 10 | $293 |
| Ascendis Pharma Endocrinology Inc ASND | 7 | $227 |
| Lilly USA, LLC LLY | 7 | $187 |
| Ascensia Diabetes Care Us Inc. | 14 | $184 |
| Averitas Pharma Inc. | 6 | $182 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $144 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $129 |
| Beta Bionics, Inc. BBNX | 5 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.